UBS Group Forecasts Strong Price Appreciation for Insulet (NASDAQ:PODD) Stock

Insulet (NASDAQ:PODD) had its price target upped by equities researchers at UBS Group from $150.00 to $171.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm currently has a “neutral” rating on the medical instruments supplier’s stock. UBS Group‘s price target suggests a potential upside of 9.53% from the company’s current price.

Several other research analysts have also recently issued reports on the company. Wells Fargo & Company increased their price objective on Insulet from $144.00 to $172.00 and gave the stock an “equal weight” rating in a research report on Thursday. Citigroup increased their target price on Insulet from $150.00 to $170.00 and gave the company a “neutral” rating in a report on Thursday. Benchmark lowered their price target on shares of Insulet from $250.00 to $185.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Stifel Nicolaus dropped their target price on Insulet from $225.00 to $180.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Finally, Raymond James Financial reaffirmed an “outperform” rating and set a $180.00 price target on shares of Insulet in a research note on Thursday, August 6th. Thirteen investment analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Insulet presently has a consensus rating of “Hold” and an average price target of $192.36.

Insulet Stock Performance

Shares of PODD stock traded down $8.90 during mid-day trading on Thursday, hitting $156.12. 1,319,217 shares of the stock were exchanged, compared to its average volume of 1,397,991. The stock’s fifty day simple moving average is $141.65 and its two-hundred day simple moving average is $178.00. The stock has a market capitalization of $10.83 billion, a price-to-earnings ratio of 29.18, a P/E/G ratio of 1.22 and a beta of 1.06. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. Insulet has a 12-month low of $126.40 and a 12-month high of $354.88.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 EPS for the quarter, topping the consensus estimate of $1.59 by $0.40. The company had revenue of $842.00 million for the quarter, compared to analyst estimates of $832.63 million. Insulet had a return on equity of 29.29% and a net margin of 12.29%. The firm’s revenue was up 19.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.24 earnings per share. On average, analysts forecast that Insulet will post 6.51 EPS for the current year.

Institutional Trading of Insulet

Several hedge funds and other institutional investors have recently modified their holdings of the business. Maryland State Retirement & Pension System grew its position in Insulet by 22.5% during the third quarter. Maryland State Retirement & Pension System now owns 4,176 shares of the medical instruments supplier’s stock valued at $545,000 after purchasing an additional 768 shares in the last quarter. Ritholtz Wealth Management acquired a new position in Insulet during the 3rd quarter valued at $276,000. Jacobi Capital Management LLC bought a new position in Insulet in the third quarter worth $40,000. New York Life Investment Management LLC boosted its holdings in Insulet by 91.5% during the third quarter. New York Life Investment Management LLC now owns 21,015 shares of the medical instruments supplier’s stock valued at $2,742,000 after purchasing an additional 10,042 shares in the last quarter. Finally, AlphaCore Capital LLC acquired a new stake in shares of Insulet during the 3rd quarter worth about $557,000.

Insulet News Roundup

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet reported Q3 adjusted EPS of $1.99, above the $1.59 consensus, while revenue rose 19.2% year over year to $842 million and also topped estimates. The company announced a $1 billion share-repurchase program and updated its 2026 outlook. Insulet Q3 earnings and revenue beat
• Positive Sentiment: Several analysts lifted their price targets after the results. Bernstein raised its target to $200 and kept an outperform rating; RBC raised its target to $180 and also maintained outperform, while Canaccord reiterated Buy at $179. RBC price-target update
• Neutral Sentiment: Other target increases came with cautious ratings: JPMorgan and Citi moved to $170, UBS to $171, and Wells Fargo to $172, while retaining neutral or equal-weight stances. RBC sees valuation as attractive but notes a more conservative 2027 outlook. RBC valuation and outlook commentary
• Negative Sentiment: Management cautioned that growth may slow in 2027 and that competitors could take some share from Omnipod. Those forward-looking concerns may be outweighing the strong quarter and contributing to the stock’s decline. CEO comments on growth and competition

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.